Abstract
Article Pepsin pretreatment corrects underestimation of 25-hydroxyvitamin D measurement by an automated immunoassay in subjects with high vitamin D binding protein levels was published on January 1, 2022 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 60, issue 1).
Highlights
Vitamin D is well known for its health benefits
We investigated whether we could correct for the underestimation of 25(OH)D in subjects with high vitamin D-binding protein (VDBP) concentrations using pepsin pretreatment in combination with the Lumipulse G 25(OH)D automated immunoassay
Assay agreement of the Lumipulse immunoassay with our LC-MS/MS method was good in most subject groups (with a slope, intercept and correlation coefficient r of 0.87, −0.76, and 0.98 in healthy subjects; 0.90, 2.1, and 0.99 in dialysis patients; 0.82, 4.9, and 0.98 in liver fibrosis patients; and 0.87, 2.77, and 0.87 in ICU patients, respectively), with the exception of pregnant women (Figure 1A and B)
Summary
Vitamin D is well known for its health benefits. The majority of circulating 25-hydroxyvitamin D (25(OH)D) is bound with high avidity to vitamin D-binding protein (VDBP). Agreement with VDSP traceable LC-MS/MS methods was moderate to poor in other populations such as pregnant women [7], and 25(OH)D concentrations were underestimated with 11– 35%, depending on the patients tested [7, 8].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
